By: Mindy Miner, PhD, HVTN Core, Seattle, WA, USA
Pfizer & BioNTech’s mRNA Vaccine Study
BNT162b2 is an investigational mRNA vaccine being developed by Pfizer and BioNTech to help prevent COVID-19, the disease caused by the SARS-CoV-2 virus. The purpose of the study is to test how well the investigational vaccine works at preventing COVID-19 disease and evaluate whether it is safe for adults and adolescents. BNT162b2 contains a small part of the genetic code for the SARS-CoV-2 spike protein. BNT162b2 does not contain any live virus. It cannot give you SARS-CoV-2 infection, nor will you get COVID-19.
Visit ClinicalTrials.gov - NCT04368728 for additional details.
The ENSEMBLE Study with Janssen’s Ad26.CoV2.S Investigational Vaccine
The Ad26.COV2.S investigational vaccine is being developed to prevent or lessen the severity of COVID-19, the disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The Ad26.COV2.S investigational vaccine includes bits of genetic material copied from the spikes of the SARS-CoV-2 virus. The goal is for the body to be immunized against COVID-19. The investigational vaccine does not contain the actual virus and cannot cause COVID-19. The ENSEMBLE study aims to test Janssen’s investigational vaccine in many different populations across the globe.
Visit ClinicalTrials.gov - NCT04505722 for additional details.
AstraZeneca Study of AZD1222
AZD1222 is an investigational vaccine being developed by AstraZeneca to prevent COVID-19, the disease caused by the SARS-CoV-2 virus.
The vaccine is based on a weakened version of a common cold (adenovirus) virus. The adenovirus vaccine has been changed so that it can’t replicate inside your body. It presents part of the COVID-19 spike protein to the body so that an immune response can be made to it. The purpose of the study is to test how well the investigational vaccine works at preventing COVID-19 disease and how safe it is.
Visit ClinicalTrials.gov - NCT04516746 for additional details.
Regeneron’s 10933 and 10987 Antibodies, the REGN-CoV2 Study
REGN-COV-2 is testing a combination of two antibodies called REGN10933 and REGN10987 to see whether they are able to prevent acquisition of SARS-CoV-2. This study will enroll approximately 2,000 adults in the United States who are living in the same household as a person who has recently tested positive for SARS-CoV-2. This will include about 1,700 participants who test SARS-CoV-2 negative at enrollment and about 300 participants who have a positive SARS-CoV-2 test result but do not have any COVID-19 symptoms.
The REGN10933 and REGN10987 antibodies are designed to bind to SARS-CoV-2 and prevent the virus from entering healthy cells. The antibodies were made in a lab by the pharmaceutical company Regeneron. REGN10933 and REGN10987 cannot give you SARS-CoV-2, nor will they make you sick with COVID-19.
Learn more about the study and the antibodies used:
- Visit www.regeneron.com/covid19 or ClinicalTrials.gov - NCT04452318 for additional information about the study.
- Press Release: Regeneron's Regn-Cov2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized Covid-19 Patients, Sept. 29, 2020
- Webcast: Regeneron COVID-19 Program Update, Sept. 29, 2020
- Volunteer Registry
Eli Lilly’s LY3819253 Antibody, the BLAZE-2 Study
BLAZE-2 is testing the LY3819253 antibody. It will be enrolling staff and residents in skilled nursing and assisted living facilities with a high risk of exposure to SARS-CoV-2. The study questions are:
- Does the antibody prevent the acquisition of SARS-CoV-2?
- Does the antibody help to prevent the development of more severe COVID-19, or does it reduce the symptoms?
The study will be conducted in the United States with up to 2,400 participants. LY3819253 is designed to bind to SARS‑CoV-2 and prevent the virus from entering healthy cells. LY3819253 was developed in a lab by the pharmaceutical company Eli Lilly. LY3819253 cannot give you SARS-CoV-2, nor will it make you sick with COVID-19.
Visit blaze2study.com or ClinicalTrials.gov - NCT04497987 for additional details. You may also call the BLAZE-2 Call Center at 718-210-9713 from 9 a.m. to 5:30 p.m. Eastern Time Monday through Friday.
For more information about the COVID-19 Prevention Network, go to: www.PreventCOVID.org.